Publications by authors named "A S Asch"
Article Synopsis
- Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have limited treatment options, prompting the investigation of magrolimab (M) combined with rituximab (R), and M combined with gemcitabine-oxaliplatin (M+R-GemOx) for long-term disease control.
- In a study involving 132 patients, M+R achieved an objective response rate (ORR) of 24%, while M+R-GemOx showed a higher ORR of 52%, with notable complete response (CR) rates of 12% and 39%, respectively.
- Both treatments were generally well tolerated, though common side effects included fatigue and anemia, with
Bladder cancer (BCa) is one of the most lethal genitourinary malignancies owing to its propensity for recurrence and poor survival. The biochemical pathway, signal transducer and activator of transcription 3 (STAT3), has gained significance as a molecular pathway that promotes proliferation, invasion, and chemoresistance. In this study, we explored the targeting of STAT3 with TTI-101 and SH5-07 in BCa and elucidated the mechanisms in three-dimensional (3D) spheroid and organoid models.
View Article and Find Full Text PDFImpact of Primary Disease Site of Involvement by Early-Stage Follicular Lymphoma on Patient Outcomes.
Clin Lymphoma Myeloma Leuk
December 2024
Introduction: Follicular lymphoma is a common non-Hodgkin lymphoma that can start in a diverse array of tissues throughout the body. While the majority of patients may be able to live many years with this disease, cure remains very difficult to achieve.
Objective: We sought to investigate the impact of follicular lymphoma primary disease site in early-stage disease on patient outcomes using a large national database.
Article Synopsis
- The study tested the combination of zandelisib (a PI3Kδ inhibitor) and zanubrutinib (a BTK inhibitor) to see if they would work better together and prevent resistance in patients with relapsed/refractory B-cell cancers.
- It involved 70 patients, with a recommended dosage of 60 mg zandelisib for Days 1-7 and 80 mg zanubrutinib twice daily over a 28-day cycle.
- The results showed an 87% response rate for follicular lymphoma and 74% for mantle cell lymphoma, with manageable side effects, indicating that the combination treatment is effective without increased toxicity.
Introduction: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a rare, highly heterogeneous group of mature T-cell neoplasms that historically has been associated with poor outcomes. We sought to investigate the influence of primary disease site on PTCL-NOS outcomes using a large national cancer registry.
Methods: Baseline clinical and demographic data including primary organ of involvement and Ann Arbor disease stage were extracted from the SEER database.